We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Medical News & Perspectives |

New Limits Advised for Anemia Drugs

Mike Mitka
JAMA. 2008;299(17):2016. doi:10.1001/jama.299.17.2016.
Text Size: A A A
Published online


An advisory panel to the US Food and Drug Administration (FDA) has recommended that the agency further limit the use of erythropoiesis-stimulating agents (ESAs) for the treatment of anemia in patients with cancer. The recommendations come in the wake of recent reports suggesting that the drugs shorten survival time and promote faster tumor growth in such patients.

On March 13, the FDA's Oncologic Drug Advisory Committee (ODAC) said that companies manufacturing ESAs should be allowed to continue marketing the drugs for approved oncological indications. But the committee recommended labeling specifying that ESAs should not be given to patients with curable cancers or metastatic breast and/or head and neck cancer, and said that the FDA should mandate the provision of consent forms to patients receiving ESAs for chemotherapy-induced anemia.

Figures in this Article



Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption

Graphic Jump LocationImage not available.

Federal health officials are considering further restrictions on the use of genetically engineered forms of erythropoietin to treat anemia in patients with cancer.

Molecule Data Source: PDB ID 1CN4



Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Polycythemia vera masked due to severe iron deficiency anemia. Hematol Oncol Stem Cell Ther Published online Sep 2, 2016;
Maternal heart rate during the first 48h postpartum: a retrospective cross sectional study. Eur J Obstet Gynecol Reprod Biol Published online Aug 31, 2016;

Care at the Close of Life: Evidence and Experience
Anemia Contributing to Fatigue

Care at the Close of Life: Evidence and Experience
Treatment of Anemia